

Supplementary material for: Eklund, M., Hellberg, O., Furuland, H., Cao, Y., & Nilsson, E. (2021). Effects of spironolactone on extrasystoles and heart rate variability in haemodialysis patients: a randomised crossover trial. *Upsala Journal of Medical Sciences*, 126. <https://doi.org/10.48101/ujms.v126.5660>

Supplemental table A. Concomitant medications.

Pharmacological agent	Number	%	Pharmacological agent	Number	%
<i>Antidiabetics</i>	6	38	<i>Drugs for CKD-MBD</i>	16	100
Insulin and analogues	5	31	CBPB	9	56
Sulfonylureas	1	6.2	Cinacalcet	2	12
			Lanthanum carbonate	2	12
<i>Antithrombotic agents</i>	8	50	Paracalcitol	1	6.2
Antiplatelet drugs	6	38	Sevelamer	10	62
Vitamin K antagonists	2	12	Vitamin D analogues	11	69
			Other	1	6.2
<i>Cardiovascular drugs</i>	12	75			
Beta blockers	8	50	<i>Potassium regulating drugs</i>	3	19
K ⁺ channel blockers	0	0	Polystyrene sulfonate	2	12
ACEi or ARB	8	50	Potassium chloride	1	6.2
CCB, vascular selective	3	19			
Organic nitrates	3	19	<i>Lipid modifying agents</i>	8	50
Other antihypertensive	1	6.2	Statins	8	50
			Bile acid sequestrants	0	0
<i>Diuretics</i>	7	44	Other	0	0
Loop diuretics	7	44			
Thiazides	0	0			

Concomitant medications in the 16 persons included in the long-term electrocardiogram analysis. Abbreviations: ACEi, Angiotensin converting enzyme inhibitor; ARB, Angiotensin receptor blocker; CBPB, Calcium based phosphate binder; CCB, Calcium channel blocker; CKD-MBD, Chronic kidney disease-mineral and bone disorder; K⁺, Potassium.